Khiron Life Sciences Corp.

KHRN.H

CA49374L3065

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 10:54:46 2023-05-05 am EDT			5-day change	1st Jan Change
0.04 ^CAD	-.--%		-.--%	-.--%

2023	Colombia's cannabis industry in crisis over regulatory, political hurdles	RE
2023	2518542 Alberta Ltd completed the acquisition of Khiron Europe Gmbh, Zerenia Clinics Limited, Khiron Life Sciences Spain SL, Khiron Life Sciences Uk and Pharmadrug Production GmbH from Khiron Life Sciences Corp..	CI

Khiron Life Sciences Corp. Announces the Launch of Its First ZereniaTM Clinic Outside of Colombia, in Lima, Peru

June 10, 2021 at 09:40 am EDT

Khiron Life Sciences Corp. announces the launch of its first ZereniaTM clinic outside of Colombia, in Lima, Peru. Following the success of the Company's clinic strategy in Colombia, the new clinic has been established as a strategic partnership between Khiron and Clinica Montesur, a specialized medical provider in Lima with over 90 physicians and more than 11,000 patient transactions annually.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	MSCI PERU (GDTR)	9,557 PTS	+0.36%	+1.64%	-
	NASDAQ COLOMBIA	379.9 PTS	+0.41%	-1.11%	-

Latest news about Khiron Life Sciences Corp.

Colombia's cannabis industry in crisis over regulatory, political hurdles	Dec. 21	RE
2518542 Alberta Ltd completed the acquisition of Khiron Europe Gmbh, Zerenia Clinics Limited, Khiron Life Sciences Spain SL, Khiron Life Sciences Uk and Pharmadrug Production GmbH from Khiron Life Sciences Corp..	Nov. 16	CI
2518542 Alberta Ltd agreed to acquire Khiron Europe Gmbh, Zerenia Clinics Limited, Khiron Life Sciences Spain SL, Khiron Life Sciences Uk and Pharmadrug Production GmbH from Khiron Life Sciences Corp. for CAD 3 million.	23-07-27	CI
Khiron Life Sciences Corp. Enters into Partnership with an Accredited 3rd Party Contract Manufacturing Organization	23-04-20	CI
Khiron Life Sciences Brief: On Filing of Audited Annual Financial Statements, Co Says Won't Make It On Or Before the Prescribed Deadline of May 1, 2023, as a Result of the Change in CFO	23-04-17	MT
Khiron Life Sciences Brief: Appointing Michael O'Connor as Chief Financial Officer, Replacing Ms. Helen Bellwood	23-04-17	MT
Khiron Life Sciences Announces CFO Changes	23-04-17	CI
Toronto Stocks Climb; TerrAscend Rises on Plans to Apply for TSX Listing	23-03-14	DJ
Khiron Life Sciences Plans Overnight Marketed Offering of Share Units	23-03-13	MT
Khiron Life Sciences Secures Additional Loan with Investment-Grade Bank	23-02-16	MT
Khiron Life Sciences Corp. Announces That Its Wholly Owned Subsidiary Zerenia Colombia Closes an Unsecured Revolving Credit Facility of CAD 580,000 with Private Financing Company in Colombia	23-02-14	CI
Khiron Life Sciences Starts Providing Insurance-covered Prescriptions in Colombia	23-01-19	MT
Khiron Edging Up as Notes NHS Reimburses Cost of Cannabis Treatment to First Zerenia Clinics UK Patient	23-01-16	MT
Khiron Life Sciences Corp. Announces Full Reimbursement by the NHS of Costs Associated to Cannabis-Based Medication and Clinic Fees for A Patient Enrolled in Zerenia Clinics UK	23-01-16	CI
Khiron Wins First Medical Cannabis Contract with Colombia's Largest Public Insurance Company	23-01-09	CI
Khiron Up 41% As Notes Government of Colombia Declares Mandatory Insurance Coverage for Medical Cannabis Products	23-01-05	MT
Transcript : Khiron Life Sciences Corp., Q3 2022 Earnings Call, Nov 30, 2022	22-11-30
Khiron Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
Khiron Begins Sales in Switzerland, Increases Offerings in Germany, UK	22-11-16	MT
Khiron Life Sciences Corp. Begins Sales in Switzerland and Expands Its Medical Cannabis Portfolio in Germany and the United Kingdom	22-11-16	CI
Khiron Life Sciences Awarded Best Latin American Cannabis Company at Benzinga Cannabis Capital Conference	22-09-13	MT
Khiron Life Sciences Corp.'s Equity Buyback announced on September 9, 2021 has expired.	22-09-12	CI
Khiron Life Sciences Up 4% after Reporting Launch of New Cannabis Products in Europe	22-09-01	MT
Khiron Launches New Cannabis Products in Europe Including Stellar Genetics from California	22-09-01	CI
Transcript : Khiron Life Sciences Corp., Q2 2022 Earnings Call, Aug 29, 2022	22-08-29

Chart Khiron Life Sciences Corp.

Duration

Period

More charts

Company Profile

Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line, the Company is focused on product sales in Latin America. The Company operates its own network of health centers (operating under the Zerenia brand) and Zerenia satellite clinics offering a suite of health, medical and surgical services, in alignment with both insurance company partners and private practice. Its subsidiaries include Khiron Life Sciences Corp. (Canada), Khiron Colombia S.A.S., Zerenia S.A.S., NettaGrowth International Inc., and others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
KHIRON LIFE SCIENCES CORP.	-.--%	6.81M
DONG-E-E-JIAO CO.,LTD.	+37.29%	6.02B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-21.28%	4.19B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+4.52%	3.25B
TASLY PHARMACEUTICAL GROUP CO., LTD	-18.16%	2.87B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-7.70%	2.37B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+41.50%	1.89B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-4.05%	1.58B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-15.56%	1.54B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-14.62%	1.5B

Alternative Medicine